US Bancorp’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-1,000
Closed -$19.3K 4031
2025
Q2
$19.3K Hold
1,000
﹤0.01% 3179
2025
Q1
$17.5K Hold
1,000
﹤0.01% 3230
2024
Q4
$23.9K Hold
1,000
﹤0.01% 3087
2024
Q3
$27.9K Hold
1,000
﹤0.01% 3003
2024
Q2
$25.3K Hold
1,000
﹤0.01% 2967
2024
Q1
$29.1K Hold
1,000
﹤0.01% 2939
2023
Q4
$24.5K Hold
1,000
﹤0.01% 2968
2023
Q3
$19.6K Hold
1,000
﹤0.01% 2889
2023
Q2
$24K Hold
1,000
﹤0.01% 2888
2023
Q1
$21.9K Hold
1,000
﹤0.01% 2945
2022
Q4
$25K Hold
1,000
﹤0.01% 2878
2022
Q3
$25K Hold
1,000
﹤0.01% 2911
2022
Q2
$22K Hold
1,000
﹤0.01% 2991
2022
Q1
$28K Hold
1,000
﹤0.01% 2891
2021
Q4
$39K Hold
1,000
﹤0.01% 2774
2021
Q3
$45K Hold
1,000
﹤0.01% 2702
2021
Q2
$50K Hold
1,000
﹤0.01% 2670
2021
Q1
$51K Hold
1,000
﹤0.01% 2572
2020
Q4
$50K Hold
1,000
﹤0.01% 2511
2020
Q3
$39K Hold
1,000
﹤0.01% 2514
2020
Q2
$43K Hold
1,000
﹤0.01% 2485
2020
Q1
$29K Hold
1,000
﹤0.01% 2588
2019
Q4
$39K Buy
+1,000
New +$29.7K ﹤0.01% 2585

Other funds holding BBC

US Bancorp's BBC Position: Q3 2025 in Review

US Bancorp sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q3 2025, closing a stake of 1,000 shares — an estimated $19.3K sold.

US Bancorp first reported a position in BBC in Q4 2019 and held it in 23 quarters. The position peaked at $51K in Q1 2021. 12 funds tracked by Wall St. Rank hold BBC as of Q3 2025.

  • US Bancorp reported no remaining Virtus Biotech Clinical Trials ETF position as of Q3 2025 after selling out during the quarter.
  • US Bancorp sold 1,000 Virtus Biotech Clinical Trials ETF shares in Q3 2025, an estimated $19.3K.
  • US Bancorp first reported a position in Virtus Biotech Clinical Trials ETF in Q4 2019 and held it in 23 quarters.
  • US Bancorp's Virtus Biotech Clinical Trials ETF position peaked at $51K in Q1 2021.
  • 12 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q3 2025.

Based on US Bancorp's 13F filing for Q3 2025, filed 12 Nov 2025.